| Name | BRD7389 |
| Description | BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. |
| In vitro | BRD7389 (1 μM) almost completely blocked Carbachol (1 mM)-stimulated cell proliferation, but has little effect on the basal level of proliferation[1]. BRD7389 (0.425, 0.85, 1.7, 3.4, 6.8 μM) induces insulin expression in mouse α-cells and induces a dose-dependent up-regulation of insulin (Ins2) mRNA, peaking at 0.85 μM. BRD7389 increases β-cell-specific gene expression in primary human islet cells. BRD7389 (0.85-6.8μM) significantly up-regulates Pdx1 mRNA expression in mouse α-cell line[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20 mg/mL (54.58 mM), Sonication and heating to 60℃ are recommended.
|
| Keywords | SNU-407 | SGK | S6Kinase | S6K | S6 Kinase | RSK3 | RSK2 | RSK1 | RSK | Ribosomal S6 Kinase (RSK) | PKG1α | Pim1 | pancreatic | islets | Inhibitor | inhibit | FLT3 | DRAK1 | diabetes | colon | CDK5/p35 | cancer | BRD-7389 | BRD7389 | BRD 7389 |
| Inhibitors Related | Ribociclib | Gilteritinib | Amantadine | 2-Chloropyrazine | Kojic acid | Quinocetone | Sorafenib | Abemaciclib | Pexidartinib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Sodium salicylate |
| Related Compound Libraries | Reprogramming Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | JAK-STAT Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |